Martee L Hensley1, Shreyaskumar R Patel2, Margaret von Mehren3, Kristen Ganjoo4, Robin L Jones5, Arthur Staddon6, Daniel Rushing7, Mohammed Milhem8, Bradley Monk9, George Wang10, Sharon McCarthy11, Roland E Knoblauch12, Trilok V Parekh13, Robert G Maki14, George D Demetri15. 1. Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: hensleym@MSKCC.ORG. 2. The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. Electronic address: spatel@mdanderson.org. 3. Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: Margaret.vonmehren@fccc.edu. 4. Stanford Hospital and Clinics, Stanford, CA, USA. Electronic address: kganjoo@stanford.edu. 5. Seattle Cancer Care Alliance/University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Electronic address: robin.jones4@nhs.net. 6. Arthur James Cancer Center, Columbus, OH, USA. Electronic address: arthurstaddon@pennoncology.com. 7. Indiana University, Simon Cancer Center, Indianapolis, IN, USA. Electronic address: drushing@iupui.edu. 8. University of Iowa Hospitals and Clinics, Iowa City, IA, USA. Electronic address: mohammed-milhem@uiowa.edu. 9. St. Joseph's Hospital & Medical Center, Phoenix, AZ, USA. Electronic address: bradley.monk@usoncology.com. 10. Janssen Research & Development LLC, Raritan, NJ, USA. Electronic address: GWang14@its.jnj.com. 11. Janssen Research & Development LLC, Raritan, NJ, USA. Electronic address: smccar15@ITS.JNJ.com. 12. Janssen Research & Development LLC, Raritan, NJ, USA. Electronic address: RKnoblau@its.jnj.com. 13. Janssen Research & Development LLC, Raritan, NJ, USA. Electronic address: TParekh1@ITS.JNJ.COM. 14. Mount Sinai School of Medicine, New York, NY, USA. Electronic address: RMaki@northwell.edu. 15. Dana-Farber Cancer Institute, Harvard Medical School, and Ludwig Center at Harvard, Boston, MA, USA. Electronic address: gdemetri@partners.org.
Abstract
OBJECTIVE: Trabectedin demonstrated significantly improved disease control in leiomyosarcoma and liposarcoma patients in a global phase 3 trial (NCT01343277). A post hoc analysis was conducted to assess the efficacy and safety of trabectedin or dacarbazine in women with uterine leiomyosarcoma (uLMS), the largest subgroup of enrolled patients (40%). METHODS: Of 577 patients randomized 2:1 to receivetrabectedin 1.5mg/m2 by 24-hour IV infusion or dacarbazine 1g/m2 by 20-120-minute IV infusion once every three weeks, 232 had uLMS (trabectedin: 144; dacarbazine: 88). The primary endpoint was overall survival (OS); secondary endpoints were progression-free survival (PFS), objective response rate (ORR), clinical benefit rate (CBR: complete responses+partial responses+stable disease [SD] for at least 18weeks), duration of response (DOR), and safety. RESULTS:PFS for trabectedin was 4.0months compared with 1.5months for dacarbazine (hazard ratio [HR]=0.57; 95% CI 0.41-0.81; P=0.0012). OS was similar (trabectedin 13.4months vs. dacarbazine 12.9months, HR=0.89; 95% CI 0.65-1.24; P=0.51) between groups. ORR was 11% with trabectedin vs. 9% with dacarbazine (P=0.82). CBR for trabectedin was 31% vs. 18% with dacarbazine (P=0.05); median DOR was 6.5months for trabectedin vs. 4.1months for dacarbazine (P=0.32). Grade 3/4 treatment-emergent adverse events observed in ≥10% of patients in the trabectedin group included transient aminotransferase (aspartate/alanine) elevations, anemia, leukopenia, and thrombocytopenia. CONCLUSIONS: In this post hoc subset analysis of patients with uLMS who had received prioranthracycline therapy, trabectedin treatment resulted in significantly longer PFS versus dacarbazine, with an acceptable safety profile. There was no difference in OS.
RCT Entities:
OBJECTIVE:Trabectedin demonstrated significantly improved disease control in leiomyosarcoma and liposarcomapatients in a global phase 3 trial (NCT01343277). A post hoc analysis was conducted to assess the efficacy and safety of trabectedin or dacarbazine in women with uterine leiomyosarcoma (uLMS), the largest subgroup of enrolled patients (40%). METHODS: Of 577 patients randomized 2:1 to receive trabectedin 1.5mg/m2 by 24-hour IV infusion or dacarbazine 1g/m2 by 20-120-minute IV infusion once every three weeks, 232 had uLMS (trabectedin: 144; dacarbazine: 88). The primary endpoint was overall survival (OS); secondary endpoints were progression-free survival (PFS), objective response rate (ORR), clinical benefit rate (CBR: complete responses+partial responses+stable disease [SD] for at least 18weeks), duration of response (DOR), and safety. RESULTS: PFS for trabectedin was 4.0months compared with 1.5months for dacarbazine (hazard ratio [HR]=0.57; 95% CI 0.41-0.81; P=0.0012). OS was similar (trabectedin 13.4months vs. dacarbazine 12.9months, HR=0.89; 95% CI 0.65-1.24; P=0.51) between groups. ORR was 11% with trabectedin vs. 9% with dacarbazine (P=0.82). CBR for trabectedin was 31% vs. 18% with dacarbazine (P=0.05); median DOR was 6.5months for trabectedin vs. 4.1months for dacarbazine (P=0.32). Grade 3/4 treatment-emergent adverse events observed in ≥10% of patients in the trabectedin group included transient aminotransferase (aspartate/alanine) elevations, anemia, leukopenia, and thrombocytopenia. CONCLUSIONS: In this post hoc subset analysis of patients with uLMS who had received prior anthracycline therapy, trabectedin treatment resulted in significantly longer PFS versus dacarbazine, with an acceptable safety profile. There was no difference in OS.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Winette T A van der Graaf; Jean-Yves Blay; Sant P Chawla; Dong-Wan Kim; Binh Bui-Nguyen; Paolo G Casali; Patrick Schöffski; Massimo Aglietta; Arthur P Staddon; Yasuo Beppu; Axel Le Cesne; Hans Gelderblom; Ian R Judson; Nobuhito Araki; Monia Ouali; Sandrine Marreaud; Rachel Hodge; Mohammed R Dewji; Corneel Coens; George D Demetri; Christopher D Fletcher; Angelo Paolo Dei Tos; Peter Hohenberger Journal: Lancet Date: 2012-05-16 Impact factor: 79.321
Authors: Bradley J Monk; John A Blessing; Daron G Street; Carolyn Y Muller; James J Burke; Martee L Hensley Journal: Gynecol Oncol Date: 2011-10-13 Impact factor: 5.482
Authors: Rebecca C Arend; Michael D Toboni; Allison M Montgomery; Robert A Burger; Alexander B Olawaiye; Bradley J Monk; Thomas J Herzog Journal: Oncologist Date: 2018-08-23
Authors: Michael J Wagner; Yuzheng Zhang; Lee D Cranmer; Elizabeth T Loggers; Graeme Black; Sabrina McDonnell; Shannon Maxwell; Rylee Johnson; Roxanne Moore; Pedro Hermida de Viveiros; Lauri Aicher; Kimberly S Smythe; Qianchuan He; Robin L Jones; Seth M Pollack Journal: Clin Cancer Res Date: 2022-06-01 Impact factor: 13.801
Authors: Martee L Hensley; Danielle Enserro; Helen Hatcher; Petronella B Ottevanger; Anders Krarup-Hansen; Jean-Yves Blay; Cyril Fisher; Katherine M Moxley; Shashikant B Lele; Jayanthi S Lea; Krishnansu S Tewari; Premal H Thaker; Oliver Zivanovic; David M O'Malley; Katina Robison; David S Miller Journal: J Clin Oncol Date: 2018-10-05 Impact factor: 44.544
Authors: Tasuku Kiyuna; Yasunori Tome; Takashi Murakami; Kei Kawaguchi; Kentaro Igarashi; Kentaro Miyake; Masuyo Miyake; Yunfeng Li; Scott D Nelson; Sarah M Dry; Arun S Singh; Tara A Russell; Irmina Elliott; Shree Ram Singh; Fuminori Kanaya; Fritz C Eilber; Robert M Hoffman Journal: BMC Cancer Date: 2018-08-20 Impact factor: 4.430